<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080079</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-9</org_study_id>
    <nct_id>NCT01080079</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis</brief_title>
  <official_title>A Subject Blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric BioTherapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric BioTherapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the iontophoretic application of terbinafine gel
      is safe and effective for teh treatment of distal subungual onychomycosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and Microbiological Improvement in nails vs placebo</measure>
    <time_frame>11 months</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Group A -Terbinafine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terbinafine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Terbinafine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terbinafine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C - Terbinafine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terbinafine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D Terbinafine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terbinafine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terbinafine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine Hydrochloride</intervention_name>
    <description>4% w/w Terbinafine Hydrochloride Gel</description>
    <arm_group_label>Group A -Terbinafine HCl</arm_group_label>
    <arm_group_label>Group B - Terbinafine HCl</arm_group_label>
    <arm_group_label>Group C - Terbinafine HCl</arm_group_label>
    <arm_group_label>Group D Terbinafine HCl</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Purified Water</intervention_name>
    <description>Purified Water</description>
    <arm_group_label>Group F - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - • Positive clinical findings for distal subungual onychomycosis as determined by clinical
        examination

          -  Must have a great toenail involvement with onychomycosis in ≥25-≤65% of the visible
             nail. (more than one nail maybe affected however only the index great toenail will be
             evaluated)

          -  Nail plate must be ≤ 3 mm thick.

          -  Must have a positive KOH and positive identification of a Dermatophyte via culture.

          -  Written informed consent must be obtained from the subject.

          -  Must be ≥ 18 and &lt; 70 years of age, unless local laws dictate otherwise.

          -  Must agree to avoid any type of pedicure or application of any nail polish product or
             nail cosmetic to the toenails after the screening visit until the conclusion of the
             trial.

          -  Must agree to take measures to avoid pregnancy during the study period

          -  Must agree to avoid the use of oral or topical antifungals unless provided by the
             investigator for the relief of symptomatic (active clinical signs) tinea pedis which
             has occurred during the treatment / follow up phase of the study. (The treatment
             provided will be Lotrimin®).

        Exclusion Criteria:

        - • The presence of proximal subungual onychomycosis or white superficial onychomycosis

          -  Fungal involvement of the lunula or less than 2 mm of clear nail from the the proximal
             nail fold

          -  Subjects with psoriasis, eczema, symptomatic (with active clinical signs) interdigital
             or plantar tinea pedis, lichen planus, or other abnormalities (e.g. traumatized or
             dystrophic nails) that could result in a clinically abnormal nail or the investigator
             thinks the current condition will compromise the integrity of the trial

          -  Any presence of dermatophytoma or onychomycotic spikes

          -  Subjects with either uncontrolled diabetes mellitus or known diabetics on
             pharmaceutical therapy or those with no palpable pedal pulse

          -  Subjects with peripheral vascular disease

          -  Subjects who are immunosuppressed - those on chronic corticosteroid therapy (see
             below), with solid organ or bone marrow transplantation, cytotoxic chemotherapy within
             the previous 12 months (or planned within the next 12 months), or HIV infection.

          -  Use of topical antifungals e.g. (clotrimazole, ketoconazole, miconazole, oxiconazole
             (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole,
             econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, tolnaftate,
             haloprogin), Zeasorb-AF Ciclopirox (e.g. Penlac® Nail Lacquer, Sanofi-Aventis) and
             corticosteroids (e.g. hydrocortisone, betamethasone, fluticasone and mometasone) in
             the preceding 15 days of Day 1, on or immediately around the area under evaluation.

          -  Use of systemic corticosteroids within 30 days preceding Day 1

          -  Use of systemic antifungals in the preceding 120 days of Day 1 including -
             (terbinafine - (Lamisil®, Novartis), Itraconazole - (Sporanox®, Janssen), fluconazole-
             (Diflucan®, Pfizer), ketoconazole, miconazole, griseofulvin (Gris-PEG®, Pedinol),
             butoconazole, terconazole, potassium iodide,.

          -  Has used any investigational drug(s) within 30 days preceding Day 1, with the
             exception of investigational systemic antifungals (120 days))

          -  Is pregnant or is a nursing mother

          -  Is a woman of child bearing potential who is not using an adequate form of
             contraception (or abstinence)

          -  Is &lt; 18 years of age, unless local laws dictate otherwise.

          -  Suffers from a condition, which, in the opinion of the medical investigator, would
             compromise his/her safety and / or the quality of the data.

          -  Subjects with a pacemaker or automatic implantable cardioverter/defibrillator.

          -  Subjects with an implantable electronic device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research, LLC</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Center, Inc</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Schoool of Podiatric Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediprobe Research, Inc</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research, Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

